Pancreatic Cancer Research

ResearcherPennsylvania State UniversityActive in the last 2 years

Nelson S. Yee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1457-9047; OpenAlex author ID A5043220508. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 1, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers, 1 trial · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper, 1 trial

Papers 21

  1. Factors Associated with Stage at Diagnosis in Pancreatic Cancer: Implications for Precision Screening and Early Detection. Last author DOI 10.3390/biomedicines14050992↗
  2. Complete response to chemotherapy in a 6-year survivor of metastatic pancreatic cancer. Co-author DOI 10.1136/bcr-2024-261008↗
  3. Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. Co-author DOI 10.3390/biomedicines8120581↗
  4. Recurrent Superior Vena Cava Syndrome in a Patient with Sarcoidosis and Pancreatic Adenocarcinoma: A Case Report and Literature Review. Last author DOI 10.3390/medicines7090056↗
  5. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Co-author DOI 10.1038/s41598-019-56268-3↗
  6. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Last author DOI 10.1200/jop.2016.017376↗
  7. TRPM8 Ion Channels as Potential Cancer Biomarker and Target in Pancreatic Cancer. Co-author DOI 10.1016/bs.apcsb.2016.01.001↗
  8. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Last author DOI 10.1200/jco.2016.67.5561↗
  9. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives. Co-author DOI 10.2174/1874467208666150716120810↗
  10. Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis. Co-author DOI 10.1242/bio.20137088↗
  11. Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma. Co-author DOI 10.2174/1574884710666151020100640↗
  12. Aberrantly Over-Expressed TRPM8 Channels in Pancreatic Adenocarcinoma: Correlation with Tumor Size/Stage and Requirement for Cancer Cells Invasion. Co-author DOI 10.3390/cells3020500↗
  13. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Co-author DOI 10.1007/978-1-4614-6176-0_5↗
  14. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗
  15. Translating discovery in zebrafish pancreatic development to human pancreatic cancer: biomarkers, targets, pathogenesis, and therapeutics. Co-author DOI 10.1089/zeb.2012.0817↗
  16. Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2011.12.007↗
  17. Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer. Co-author DOI 10.1242/bio.2012539↗
  18. TRPM8 ion channel is aberrantly expressed and required for preventing replicative senescence in pancreatic adenocarcinoma: potential role of TRPM8 as a biomark… Co-author DOI 10.4161/cbt.20079↗
  19. TRPM7 and TRPM8 Ion Channels in Pancreatic Adenocarcinoma: Potential Roles as Cancer Biomarkers and Targets. Co-author DOI 10.6064/2012/415158↗
  20. Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting. Co-author DOI 10.4161/cbt.11.11.16573↗
  21. Pancreatic Adenocarcinoma Associated With Werner's Syndrome (Adult-Onset Progeria). First author PMID 21464868↗

Trials 2

  1. CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy Principal investigator NCT07016971↗
  2. Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Principal investigator NCT03861702↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elen Deng · 1 shared paper, 2026 · strength 0.43
  2. Rosemary K. Yee · 8 shared papers, 2012–2015 · strength 0.42
  3. June S. Peng · 1 shared paper, 2024 · strength 0.31
  4. Cynthia E. Burke · 1 shared paper, 2024 · strength 0.31
  5. Edward P. Balaban · 2 shared papers, 2016–2017 · strength 0.16
  6. Siyang Zheng · 1 shared paper, 2020 · strength 0.16
  7. Ganesh Shenoy · 1 shared paper, 2020 · strength 0.13
  8. Allan Lipton · 1 shared paper, 2019 · strength 0.08
  9. M.A. Karsdal · 1 shared paper, 2019 · strength 0.08
  10. Nicholas Willumsen · 1 shared paper, 2019 · strength 0.08
  11. Stephen G. Chun · 2 shared papers, 2011–2012 · strength 0.07
  12. Andrew H. Ko · 1 shared paper, 2016 · strength 0.05
  13. Alok A. Khorana · 1 shared paper, 2016 · strength 0.05
  14. Milind M. Javle · 1 shared paper, 2016 · strength 0.05
  15. Anitra Engebretson · 1 shared paper, 2016 · strength 0.05
  16. John H. Strickler · 1 shared paper, 2016 · strength 0.05
  17. Jennifer Rachel Eads · 1 shared paper, 2016 · strength 0.05
  18. Somnath Mukherjee · 1 shared paper, 2016 · strength 0.05
  19. Joseph M. Herman · 1 shared paper, 2016 · strength 0.05
  20. Peter J. Allen · 1 shared paper, 2016 · strength 0.05
  21. Christopher H. Crane · 1 shared paper, 2016 · strength 0.05
  22. Al B. Benson · 1 shared paper, 2016 · strength 0.05
  23. Peter K. Bryant-Greenwood · 1 shared paper, 2011 · strength 0.03
  24. Daniel Berg · 1 shared paper, 2013 · strength 0.03
  25. Jessemae L. Welsh · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.